Peptide-based Delivery of Therapeutic Nucleic Acids Targeting Neurodegenerative Diseases

The technology pertains to the potential of TARBP-BTP as a new fusion protein platform developed to mediate efficient RNAi in the brain and knockdown of BACE1 to reduce build-up of toxic peptides in neurodegenerative condition namely Alzheimer's Disease (AD).

The technology pertains to the potential and utility of TARBP-BTP, a new fusion protein that fosters the efficient delivery of siRNA to the brain and hence mediate the knockdown of target genes responsible for early onset of neurodegenerative disorders and would also serve unmet needs for incurable neurological conditions. e.g. Huntington's Disease, Alzheimer's Disease (AD).

An excellent method for delivering siRNA across the blood-brain barrier for the intervention of neurodegenerative diseases.